Emerging agents such as ANGPTL3 and apoC-III inhibitors, as well as novel therapies like inclisiran and icosapent ethyl, offer promising avenues for further reducing cardiovascular risk in patients with persistent dyslipidemia after ACS. Here, ANGPTL3 is linked to metabolic syndrome.